Field evaluation of melatonin implants to advance the breeding season in 1-year-old farmed red deer hinds

The efficacy of controlled-release melatonin implants to advance the onset of the breeding season was assessed in 1-year-old red deer hinds on five commercial deer farms in various localities in the North Island of New Zealand. Between 44 and 60 hinds in each of six herds were equally divided among treatment and control groups at each site. Melatonin treatment commenced between 27 November and 16 December and was achieved by the subcutaneous administration of two 18 mg melatonin implants. Three doses were given at about 30 day intervals. Two adult stags for each hind group were treated with three 18 mg melatonin implants concurrently on either two or three occasions. On each property, treated and control hinds were joined as one herd to treated stags commencing 30 January-10 February and concluding 15 May-2 June. The hinds in the four experimental herds underwent rectal ultrasound examination May-June to estimate conception rate and foetal age. Calving dates, hind and calf mortalities, weaning weights, and the antler growth cycle and harvesting data were recorded. Overall, treatment with melatonin resulted in an average advance of the median calving date of 22 days (range 12-36 days) when compared with untreated controls in the same herds. Pregnancy rates were 91.3-100% in treated hinds and 63.6-100% in untreated hinds. There were no differences in calf mortality or calf sex ratio between treated and untreated groups. No hind deaths could be attributed to melatonin treatment. The weaning weights of calves were 5.68 kg and 4.43 kg heavier for the male and female offspring of treated hinds respectively, compared with those of control hinds. Treated stags commenced rutting behaviour earlier than normal and the antler casting and growth cycle was advanced. Treatment resulted in advancement of the seasonal pattern of coat changes in hinds and stags, but no untoward side effects of the melatonin treatments were observed.     

Facial eczema in goats: the toxicity of sporidesmin in goats and its pathology

Groups of six goats were orally dosed with sporidesmin at rates of 0.3, 0.6, 1.2 and 2.4 mg of sporidesmin per kg body weight and their responses up to 6 weeks later compared with those of sheep dosed at the same time. Clinical facial eczema and pathological lesions similar to those found in sheep were found in all the goat breeds, but at higher dose rates of sporidesmin than those which caused equivalent lesions in sheep. Saanens were the most susceptible goat breed, requiring 2-4 times as much sporidesmin as sheep to achieve similar effects. G4 and feral goats required 4-8 times the sheep dose of sporidesmin to obtain similar responses. Gamma-glutamyltransferase reached its highest serum levels after 20 days while glutamate dehydrogenase and aspartate aminotransferase reached their highest levels between 10 and 20 days. Alkaline phosphatase did not rise consistently to high levels in affected goats. The elevation in aspartate aminotransferase levels tended to be early and transient; glutamate dehydrogenase early and prolonged; gamma-glutamyltransferase late and prolonged, and'alkaline phosphatase late and minor. There was considerable individual variation in the time at which elevations occurred and the levels which enzymes reached. Cholesterol and bilirubin levels were high if liver injury was severe.     

Proposed criteria for classification of acute myeloid leukemia in dogs and cats

Blood and bone marrow smears from 49 dogs and cats, believed to have myeloproliferative disorders (MPD), were examined by a panel of 10 clinical pathologists to develop proposals for classification of acute myeloid leukemia (AML) in these species. French-American-British (FAB) group and National Cancer Institute (NCI) workshop definitions and criteria developed for classification of AML in humans were adapted. Major modifications entailed revision of definitions of blast cells as applied to the dog and cat, broadening the scope of leukemia classification, and making provisions for differentiating erythremic myelosis and undifferentiated MPD. A consensus cytomorphologic diagnosis was reached in 39 (79.6%) cases comprising 26 of AML, 10 of myelodysplastic syndrome (MDS), and 3 of acute lymphoblastic leukemia (ALL). Diagnostic concordance for these diseases varied from 60 to 81% (mean 73.3 +/- 7.1%) and interobserver agreement ranged from 51.3 to 84.6% (mean 73.1 +/- 9.3%). Various subtypes of AML identified included Ml, M2, M4, M5a, M5b, and M6. Acute undifferentiated leukemia (AUL) was recognized as a specific entity. M3 was not encountered, but this subclass was retained as a diagnostic possibility. The designations M6Er and MDS-Er were introduced where the suffix "Er" indicated preponderance of erythroid component. Chief hematologic abnormalities included circulating blast cells in 98% of the cases, with 36.7% cases having >30% blast cells, and thrombocytopenia and anemia in approximately 86 to 88% of the cases. Bone marrow examination revealed panmyeloid dysplastic changes, particularly variable numbers of megaloblastoid rubriblasts and rubricytes in all AML subtypes and increased numbers of eosinophils in MDS. Cytochemical patterns of neutrophilic markers were evident in most cases of Ml and M2, while monocytic markers were primarily seen in M5a and M5b cases. It is proposed that well-prepared, Romanowsky-stained blood and bone marrow smears should be examined to determine blast cell types and percentages for cytomorphologic diagnosis of AML. Carefully selected areas of stained films presenting adequate cellular details should be used to count a minimum of 200 cells. In cases with borderline diagnosis, at least 500 cells should be counted. The identity of blast cells should be ascertained using appropriate cytochemical markers of neutrophilic, monocytic, and megakaryocytic differentiation. A blast cell count of > 30% in blood and/or bone marrow indicates AML or AUL, while a count of < 30% blasts in bone marrow suggests MDS, chronic myeloid leukemias, or even a leukemoid reaction. Myeloblasts, monoblasts, and megakaryoblasts comprise the blast cell count. The FAB approach with additional criteria should be used to distinguish AUL and various subtypes of AML (Ml to M7 and M6Er) and to differentiate MDS, MDS-ER, chronic myeloid leukemias, and leukemoid reaction. Bone marrow core biopsy and electron microscopy may be required to confirm the specific diagnosis. Immunophenotyping with lineage specific antibodies is in its infancy in veterinary medicine. Development of this technique is encouraged to establish an undisputed identity of blast cells. Validity of the proposed criteria needs to be substantiated in large prospective and retrospective studies. Similarly, clinical relevance of cytomorphologic, cytochemical, and immunophenotypic characterizations of AML in dogs and cats remains to be determined.     

Some nutritional and genetic considerations in the performance testing of beef bulls

Performance testing started after it was recognized that growth traits were heritable. In the early years of performance testing there was a tendency to feed higher levels of energy for longer periods of time. More recently, the trend has been to feed lower levels of energy for shorter periods. There are still differences in opinion as to the appropriate level of energy to use. Although it is important that the level of energy fed is adequate to correctly establish a bull's ability to gain, it is essential to know that it will pose no risk of impaired spermatogenesis or cause any degree of laminitis. Clinical observations and research on overfeeding clearly show that both libido and spermatogenesis can be impaired by excess energy intake. The damage in 2-year-old bulls can be very extensive and in some animals it may not be reversible. The scant amount of research in yearling bulls indicates that there is considerable potential danger from overfeeding energy as well. Test stations are under used in regard to performing research that would help identify heritable defects that would interfere with the productive and reproductive efficiency of beef cattle. The first performance testing programs emphasized average daily gain from weaning to 1 year of age, so "performance" has traditionally meant rate of gain to most cattle raisers. The term "performance" is now starting to acquire a broader and more inclusive definition. For many breeders, it now includes weight per day of age, which is in part a maternal trait, and some kind of male evaluation for reproductive potential that can also be extrapolated to the female side. One of the first breakthroughs in this regard was to recognize the heritability of testicular size, and that testicular size could be fairly accurately determined by scrotal circumference measurement. It was also found that there was a favorable relationship between larger testicle size and the ability to produce high quality semen. As a result, it became a common practice to include scrotal circumference measurements in the published bull test results. However, many test station patrons were, and still are, content to consider the scrotal circumference measurement alone as an evaluation of a bull's breeding potential. Unfortunately, less than half of the bulls finishing a performance test at ages ranging from 11 to 14 months will be able to produce semen of completely acceptable quality.(ABSTRACT TRUNCATED AT 400 WORDS)